Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
1 hedge funds and large institutions have $12.8M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
18% more capital invested
Capital invested by funds: $10.8M → $12.8M (+$1.98M)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.04M |
Top Sellers
BHVN Hedge Fund Activity: Q3 2023 in Review
1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2023, worth a combined $12.8M — up 18% from $10.8M a quarter earlier.
Fund positioning in BHVN was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $1.04M.
- 1 institutional investor held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $12.8M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2023, up 18% quarter-over-quarter.
- 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2023 and 0 closed out.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2023 was Knoll Capital Management, an estimated $1.04M added.
Based on aggregated 13F filings for Q3 2023.